查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1985838

马匹保健市场：依产品类型、疾病、给药途径及最终用户划分－2026-2032年全球市场预测

Equine Healthcare Market by Product Type, Disease Indication, Route Of Administration, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，马匹保健市场价值将达到 37 亿美元，到 2026 年将成长到 39.5 亿美元，到 2032 年将达到 59.3 亿美元，复合年增长率为 6.97%。

主要市场统计数据
基准年 2025 37亿美元
预计年份：2026年 39.5亿美元
预测年份 2032 59.3亿美元
复合年增长率 (%) 6.97%

一个关于现代马匹医疗保健优先事项的权威框架，强调预防、综合诊断和协作临床创新。

马匹医疗保健产业正处于一个转折点，临床需求、马主期望和技术能力在此交汇，迫使医疗服务和产品开发的优先事项重新调整。随着预防和健康维护变得日益重要，人们对能够早期发现疾病的诊断方法以及支持马匹长期运动能力和生活品质的治疗方法越来越感兴趣。因此，从临床医生到马主，相关人员都在重新审视他们的兽医实践和筹资策略，以体现一种更积极主动的马匹健康管理模式。

技术进步、不断发展的护理服务模式和马主期望如何融合，重新定义马匹医疗保健服务和产品创新。

在技​​术成熟、疾病管理方法不断演进以及相关人员行为转变的推动下，马匹医疗保健领域正经历着一场变革。先进的影像技术和即时诊断技术正在降低诊断的不确定性，并缩短干预时间。同时，穿戴式监测平台能够持续收集数据，从而支持制定个人化的护理方案。此外，治疗方法也日益多样化，靶向药物和旨在促进康復和提升运动表现的专用饲料添加剂的出现，为临床医生和马主提供了更多治疗选择。

评估近期贸易政策转变对营运和供应链的影响，这些转变正在重组整个马匹医疗保健行业的采购、供应商选择和物流优先事项。

美国近期关税调整为整个马匹医疗保健产业的供应链、筹资策略和产品生命週期规划带来了复杂影响。进口零件和成品关税的提高迫使製造商和经销商重新评估与供应商的关係，尽可能优先考虑在地采购，并调整物流结构以维持获利能力和供应的连续性。这些调整对医疗设备、诊断试剂和某些药品的供应、前置作业时间和成本结构产生了重大影响。

将产品类型、最终用户、疾病适应症和给药途径与策略创新和商业化路径相结合的综合細項分析。

有效的细分框架能够识别产品类型、最终用户、疾病适应症和给药途径等创新与需求交汇点，从而为有针对性的开发和商业化提供蓝图。就产品类型而言，其范围涵盖医疗设备、诊断试剂、饲料添加剂、药品和疫苗。在医疗设备领域，机会体现在用于支援持续评估的监测设备、用于治疗骨骼和关节疾病的整形外科器械以及用于实现先进治疗的外科器械。诊断试剂包括影像方法、临床检测和照护现场技术，这些技术能够帮助临床医生在临床环境中快速做出决策。饲料添加剂属于矿物质、营养素和维生素组合药物的范畴，旨在促进整体健康和恢復。药品包括抗发炎药、驱虫药、抗生素和荷尔蒙。在抗发炎药物中，皮质类固醇和非类固醇消炎剂(NSAIDs) 两大类会影响治疗方法选择，而驱虫药则包括体外和体内寄生虫控制药物。马匹护理用抗生素分为β-内酰胺类、大环内酯类和四环霉素，激素则分为生长促进剂和生殖刺激剂。疫苗有灭活疫苗、减毒活病毒疫苗和重组疫苗三种形式，每种疫苗的储存和使用方法各不相同。

美洲、欧洲、中东、非洲和亚太地区的区域差异和战略机会为市场进入和研发优先事项提供了重要的见解。

区域趋势决定了投资、研究重点和应用最为集中的地区，了解这些差异对于决定市场准入和合作伙伴关係至关重要。在美洲，先进的临床基础设施、饲主的高度参与以及蓬勃发展的伴侣马和竞技马文化，正在推动对先进诊断技术、专业治疗方法和综合护理模式的需求。该地区优先考虑循证干预措施，较早采用了远端监测和远端保健服务，并支持特定领域的优质化护理。

竞争分析着重于证据生成、供应链敏捷性和策略伙伴关係关係，以推动差异化和市场渗透。

马匹医疗保健领域的竞争格局呈现出多元化的特点，既有成熟的动物用药品公司，也有专业的医疗设备诊断设备公司、兽药分销网络，以及专注于小众疗法和数位化监测的敏捷型Start-Ups。老字型大小企业往往凭藉其规模、监管经验和广泛的分销网络，在多个产品类型中保持市场地位；而专业公司则凭藉深厚的临床专业知识、针对性的技术平台以及与兽医的紧密合作展开竞争。新参与企业则透过数位化工具、即时诊断和配方创新，降低使用门槛，提高饲主参与度，进而带来颠覆性的潜在竞争优势。

为产业领导者提供切实可行的策略方法，以增强韧性、临床验证创新并透过综合商业性方法加速推广应用。

产业领导者应优先考虑一系列切实可行的倡议，以平衡短期业务永续营运与长期创新和实证累积。首先，他们应投资于供应链透明度和冗余性，以减轻贸易政策波动和零件短缺对其营运的影响。透过与多家合格供应商建立合作关係并加强物流规划，企业可以在维持品质标准的同时降低业务中断的风险。

一个严谨、多方面的研究框架，结合了主要相关人员的见解、监管审查和跨领域分析，得出可操作的结论。

本报告的研究融合了多种定性和定量方法，以确保得出可靠且可操作的结论。主要研究包括对兽医、实验室技术人员、行业高管和马主进行结构化访谈，以了解他们对临床需求、推广障碍和产品表现的不同观点。次要研究则包括对同行评审文献、监管指南、技术标准和公共文件的全面审查，以获取基于检验资讯来源的观察结果，并分析区域差异。

对临床检验、互通性和强大的营运系统如何决定马匹医疗保健的未来成功进行综合分析和展望。

总之，在技术进步、护理模式演变以及马主和临床医生日益增长的期望的推动下，马匹医疗保健产业正经历着重大变革。这些因素为那些能够提供明确临床价值、易于实践且拥有稳健供应链的解决方案创造了机会。那些能够将严格的临床检验与切实可行的商业化策略相结合，同时又能灵活适应当地法规和运作实际情况的机构，将最终获得成功。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：马匹保健市场：依产品类型划分

  • 医疗设备
    • 监测
    • 整形外科
    • 手术器械
  • 诊断药物
    • 诊断影像
    • 检查
    • 护理点
  • 饲料添加剂
    • 矿物质补充剂
    • 营养补充品
    • 维生素补充剂
  • 製药
    • 抗发炎药
      • 皮质类固醇
      • NSAIDs
    • 驱虫
      • 体外寄生虫控製剂
      • 体内寄生虫控製剂
    • 抗生素
      • β-内酰胺
      • 大环内酯类
      • 四环霉素
    • 荷尔蒙
      • 生长
      • 生殖
  • 疫苗
    • 失活
    • 活病毒疫苗
    • 重组

第九章：马匹保健市场：依疾病指征划分

  • 消化系统疾病
    • 绞痛
    • 腹泻
    • 溃疡
  • 感染疾病
    • 细菌
    • 寄生虫
    • 病毒性的
  • 肌肉骨骼疾病
    • 关节疾病
    • 整形外科损伤
    • 软组织损伤
  • 生殖疾病
    • 子宫内膜炎
    • 不孕症
  • 呼吸系统疾病
    • 下呼吸道
    • 上呼吸道

第十章：马匹保健市场：依给药途径划分

  • 吸入
    • 干粉
    • 雾化
  • 注射药物
    • 肌肉内部
    • 静脉
    • 皮下
  • 口服
    • 液体
    • 粉末
    • 药片
  • 外用
    • 奶油
    • 凝胶
    • 喷

第十一章：马匹保健市场：依最终用户划分

  • 马主
    • 养殖场
    • 个人所有者
  • 网路药房
    • OTC
    • 处方药
  • 研究机构
    • 私人的
    • 一般的
  • 动物医院
    • 大型动物医院
    • 私人诊所

第十二章：马匹保健市场：依地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章：马匹保健市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章：马匹保健市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国马匹医疗保健市场

第十六章：中国马匹保健市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Bimeda, Inc.
  • Boehringer Ingelheim GmbH
  • Ceva Sante Animale SA
  • Dechra Pharmaceuticals PLC
  • Elanco Animal Health Incorporated
  • Merck & Co., Inc.
  • Norbrook Laboratories Limited
  • Vetoquinol SA
  • Virbac SA
  • Zoetis Inc.
Product Code: MRR-3F223D52475E

The Equine Healthcare Market was valued at USD 3.70 billion in 2025 and is projected to grow to USD 3.95 billion in 2026, with a CAGR of 6.97%, reaching USD 5.93 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.70 billion
Estimated Year [2026] USD 3.95 billion
Forecast Year [2032] USD 5.93 billion
CAGR (%) 6.97%

An authoritative framing of contemporary equine healthcare priorities emphasizing prevention, diagnostic integration, and collaborative clinical innovation

The equine healthcare landscape is at an inflection point where clinical imperatives, owner expectations, and technological capabilities converge to reshape priorities across care delivery and product development. Prevention and wellness are increasingly central, with growing emphasis on diagnostics that enable early detection and on therapeutics that support long-term performance and quality of life. As a result, stakeholders from clinicians to owners are adapting practices and procurement strategies to reflect a more proactive model of equine health management.

Transitioning from a reactive model toward preventive care requires new workflows, investments in monitoring and diagnostics, and greater collaboration between veterinary practitioners, research laboratories, and product developers. These shifts are driven by rising expectations for outcomes, the need for evidence-based interventions, and the broader availability of digital tools that permit remote monitoring and data-driven decision-making. Consequently, organizations operating within this space must reconcile traditional clinical approaches with innovations that promise improved detection, targeted therapies, and measurable welfare gains.

Given these dynamics, the opening of any strategic initiative should emphasize alignment across clinical, commercial, and owner constituencies. Clarity of purpose, coupled with pragmatic pathways for piloting and scaling new technologies, will determine which innovations achieve traction. Ultimately, the equine healthcare sector is moving toward a more integrated, data-informed paradigm that rewards collaboration, rigorous validation, and a clear orientation toward long-term animal welfare.

How technological advances, shifting care delivery models, and owner expectations are coalescing to redefine equine healthcare delivery and product innovation

The equine healthcare environment is experiencing transformative shifts driven by technological maturation, evolving disease management philosophies, and changes in stakeholder behavior. Advanced imaging and point-of-care diagnostics are reducing diagnostic uncertainty and shortening time to intervention, while wearable monitoring platforms are enabling continuous data capture that supports individualized care plans. At the same time, therapeutics are diversifying with targeted pharmaceuticals and specialized feed supplements designed to support recovery and performance, thereby broadening treatment pathways available to clinicians and owners alike.

Concurrently, veterinary practices are adapting to new revenue and care models that emphasize telemedicine, remote monitoring, and subscription-based wellness programs. These operational shifts are accompanied by enhanced expectations from owners for transparency, convenience, and measurable outcomes, which in turn accelerate adoption of services that deliver real-time insights and demonstrable benefits. Research laboratories are responding by prioritizing translational studies that validate diagnostic tools and therapeutic regimens, creating a feedback loop between clinical practice and scientific investigation.

Moreover, regulatory thinking and supply chain resilience are influencing product strategies, prompting manufacturers to invest in formulation stability, cold-chain logistics, and simplified administration routes. Taken together, these trends are not isolated; rather, they reinforce one another to create a more interconnected and agile ecosystem where innovations that demonstrate value and ease of use are most likely to scale.

Assessing the operational and supply chain consequences of recent trade policy shifts that are reshaping procurement, sourcing, and logistics priorities across equine healthcare

Recent tariff changes in the United States have introduced a layer of complexity that affects supply chains, sourcing strategies, and product lifecycle planning across the equine healthcare sector. Increased duties on imported components and finished products have prompted manufacturers and distributors to reassess supplier relationships, prioritize local sourcing where feasible, and reconfigure logistics to preserve margin and continuity of supply. These adjustments have practical implications for the availability, lead times, and cost structure of devices, diagnostics, and select pharmaceutical products.

In response, many stakeholders have pursued diversification strategies to mitigate exposure to single-source dependencies. Manufacturers are exploring alternative manufacturing bases and dual-sourcing arrangements, while distributors and large veterinary practices are intensifying inventory planning and safety stock policies to offset lead-time volatility. At the same time, contract manufacturers and domestic suppliers are experiencing increased interest from clients seeking reliable alternatives to cross-border shipments, which reshapes negotiation dynamics and capacity planning within the industry.

Regulatory compliance and labeling requirements have also become more salient in procurement decisions, as products that must transit complex customs regimes can face additional scrutiny and delay. Consequently, procurement teams are allocating more resources to customs expertise and supplier qualification, while research laboratories and clinicians are prioritizing products whose supply chains offer demonstrable resilience. The combined effect is a market that values transparency, redundancy, and flexibility in the face of evolving trade policies.

Comprehensive segmentation analysis mapping product types, end users, disease indications, and administration routes to strategic innovation and commercial pathways

An effective segmentation framework reveals where innovation and demand intersect across product types, end users, disease indications, and routes of administration, providing a roadmap for targeted development and commercialization. When exploring product type, the landscape encompasses devices, diagnostics, feed supplements, pharmaceuticals, and vaccines. Within devices there are opportunities in monitoring devices that support continuous assessment, orthopedic instruments that address bone and joint conditions, and surgical instruments that enable advanced interventions. Diagnostics span imaging modalities, laboratory-based assays, and point-of-care technologies that bring faster decision-making into clinical contexts. Feed supplements divide into mineral, nutritional, and vitamin formulations that support systemic health and recovery. Pharmaceuticals include anti-inflammatories, anti-parasitic agents, antibiotics, and hormones; within anti-inflammatories the categories of corticosteroids and nonsteroidal anti-inflammatory drugs shape therapeutic choice, while anti-parasitic solutions encompass ectoparasiticides and endoparasiticides. Antibiotic classes relevant to equine care include beta lactams, macrolides, and tetracyclines, and hormones are differentiated by growth- versus reproductive-focused agents. Vaccines are offered in inactivated, live attenuated, and recombinant formats, each with distinct storage and administration considerations.

From an end user perspective, the ecosystem includes equine owners, online pharmacies, research laboratories, and veterinary practices. Equine owners are comprised of breeding farms and individual owners who have differing priorities around management scale and investment in preventive care. Online pharmacies operate across over-the-counter and prescription channels, providing convenience and range but requiring careful clinical oversight. Research laboratories are characterized by private and public institutions that drive innovation and validation, whereas veterinary practices range from large animal hospitals with integrated services to private practices focused on personalized care. Disease indication segmentation likewise highlights areas of clinical need and product alignment: digestive disorders such as colic, diarrhea, and ulcers demand rapid diagnostic and supportive care; infectious diseases categorized as bacterial, parasitic, and viral require integrated prevention and treatment strategies; musculoskeletal disorders covering joint disorders, orthopedic injuries, and soft tissue injuries benefit from combined rehabilitative and pharmaceutical approaches; reproductive disorders including endometritis and infertility intersect with both therapeutic and diagnostic solutions; respiratory disorders divided into lower and upper respiratory conditions necessitate specific administration routes and supportive care plans.

Considering route of administration clarifies development and adoption dynamics across inhalation, injectable, oral, and topical options. Inhalation approaches include dry powder delivery and nebulization, both suited for targeted respiratory interventions. Injectable formats encompass intramuscular, intravenous, and subcutaneous routes that influence onset and dosing strategies. Oral delivery consists of liquids, powders, and tablets that prioritize ease of administration for at-home care scenarios. Topical therapies in creams, gels, and sprays enable localized treatment with minimal systemic exposure. By mapping these segmentation dimensions together, developers and clinicians can better prioritize investments and tailor offerings to the specific needs and constraints of each user group and indication.

Regional differentiation and strategic opportunities across the Americas, Europe Middle East and Africa, and Asia Pacific that inform go to market and R D prioritization

Regional dynamics shape where investment, research emphasis, and adoption are most pronounced, and understanding these differences is essential for market entry and partnership decisions. In the Americas, a combination of advanced clinical infrastructure, strong owner engagement, and a thriving companion and performance equine culture drives demand for diagnostic sophistication, specialized therapeutics, and integrated care models. This region prioritizes high-evidence interventions and shows early adoption for remote monitoring and telehealth-enabled services, which supports a premiumization of care in certain segments.

Within the Europe, Middle East & Africa cluster, variability is pronounced across regulatory environments and veterinary practice norms, yet there is consistent momentum toward harmonized standards of care, particularly for infectious disease surveillance and vaccination strategies. Public-private collaboration and strong research networks in parts of this region are facilitating multicenter studies and translational research, while some markets emphasize cost-effective formulations and pragmatic protocols suited to diverse practice settings.

Asia-Pacific presents a mix of rapid clinical modernization, expanding middle-class ownership of performance and leisure horses, and an increasing focus on local manufacturing capability. In this region, demand growth is often accompanied by targeted investments in domestic research and production, and regulatory pathways continue to evolve to accommodate a broader array of diagnostics and therapeutics. Taken together, each geographic cluster offers distinct opportunities and constraints, so prioritizing regional strategies that account for clinical practice patterns, regulatory frameworks, and local supply chain realities will yield the most sustainable outcomes.

An assessment of competitive dynamics emphasizing evidence generation, supply chain agility, and strategic partnerships that drive differentiation and adoption

Competitive dynamics in equine healthcare are defined by a mix of established animal health manufacturers, specialist device and diagnostics firms, veterinary distribution networks, and agile start-ups focused on niche therapeutics or digital monitoring. Established players tend to leverage scale, regulatory experience, and broad distribution to maintain presence across multiple product categories, while specialist firms compete on deep clinical expertise, targeted technology platforms, and close alignment with veterinary practitioners. New entrants bring disruptive potential through digital tools, point-of-care diagnostics, and formulation innovations that lower barriers to use and enhance owner engagement.

Partnerships between device makers and diagnostic developers are increasingly common, enabling integrated solutions that combine monitoring, data analytics, and therapeutic recommendations. Additionally, collaborations between research laboratories and industry are accelerating translational work that validates new interventions under clinical conditions. Distribution channels also matter: online pharmacies and specialized veterinary distributors influence product visibility and access, while large animal hospitals and private practices shape clinical adoption based on real-world performance and ease of integration into care pathways.

Intellectual property, regulatory experience, and manufacturing agility are differentiators that influence competitive positioning. Firms that can demonstrate clinical outcomes, streamline administration, and provide robust support for practitioners will be better positioned to capture preference. Ultimately, company strategies that emphasize evidence generation, supply chain reliability, and tailored commercial engagement are most likely to succeed in a complex and clinically driven market.

Practical strategic initiatives for industry leaders to strengthen resilience, validate innovations clinically, and accelerate adoption through integrated commercial approaches

Industry leaders should prioritize a set of actionable initiatives that balance near-term operational resilience with longer-term innovation and evidence development. First, invest in supply chain transparency and redundancy to mitigate the operational impacts of trade policy shifts and component scarcity. By fostering relationships with multiple qualified suppliers and strengthening logistics planning, organizations can reduce disruption risk while maintaining quality standards.

Second, accelerate clinical validation programs that pair diagnostics with therapeutics to demonstrate real-world outcomes. Rigorous, translational studies that engage veterinary practices and research laboratories will unlock practitioner confidence and facilitate broader adoption. Third, embrace digital integration by deploying monitoring platforms and telemedicine workflows that improve continuity of care and create value through data-driven insights. These tools should be designed for ease of use and seamless integration into existing clinical systems.

Fourth, tailor commercial approaches to end-user segments by recognizing differences between breeding farms and individual owners, and by developing route-of-administration strategies that prioritize adherence and practicality. Fifth, explore strategic alliances that combine complementary strengths across device, diagnostic, and pharmaceutical domains to deliver bundled offerings aligned with clinical pathways. Finally, commit to regulatory and compliance excellence to expedite approvals and ensure consistent market access. Together, these actions provide a pragmatic roadmap for advancing both business resilience and clinical impact.

A rigorous multi-method research framework combining primary stakeholder insights, regulatory review, and cross segmentation analysis to support actionable conclusions

The research underpinning this report synthesizes multiple qualitative and quantitative approaches to ensure robust, actionable findings. Primary research included structured interviews with veterinary practitioners, laboratory scientists, industry executives, and equine owners to capture diverse perspectives on clinical needs, adoption barriers, and product performance. Secondary research involved a careful review of peer-reviewed literature, regulatory guidance, technical standards, and public policy documents to ground observations in validated sources and to contextualize regional differences.

Analytical methods incorporated cross-segmentation mapping to identify where product types, end users, disease indications, and routes of administration intersect with unmet needs. Supply chain and trade policy analyses were conducted using customs data, logistics performance indicators, and public trade notices to assess operational vulnerabilities. Competitive landscape analysis combined patent filings, product registries, and clinical trial registries to evaluate innovation trajectories and differentiation strategies. Throughout the study, methods emphasized triangulation of evidence, iterative validation with subject-matter experts, and sensitivity to regional regulatory and practice variations.

This layered methodology ensures conclusions are grounded in observed practice and documented evidence while remaining sensitive to emerging trends. Where primary data were limited, findings were qualified and cross-checked to preserve analytic integrity, and recommendations were formulated to be pragmatic and implementable across a range of organizational contexts.

Synthesis and forward looking perspective on how clinical validation, interoperability, and resilient operations will determine future success in equine healthcare

In closing, the equine healthcare sector is undergoing meaningful evolution driven by technological advances, shifting care models, and heightened expectations from owners and clinicians. These forces are creating opportunities for solutions that deliver clear clinical value, are easy to integrate into practice, and exhibit resilient supply chains. Success will favor organizations that can marry rigorous clinical validation with pragmatic commercialization strategies, while also demonstrating responsiveness to regional regulatory and operational realities.

Going forward, stakeholders who invest in translational research, prioritize interoperability between diagnostics and therapeutics, and engage owners through user-friendly platforms will secure competitive advantage. Moreover, those who proactively address supply chain and policy risks through diversified sourcing and robust logistics planning will be better equipped to sustain operations in a fluid trade environment. Ultimately, the most impactful advances will emerge from collaborations that bridge research, clinical practice, and product development, producing interventions that meaningfully enhance equine welfare and performance.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Equine Healthcare Market, by Product Type

  • 8.1. Devices
    • 8.1.1. Monitoring
    • 8.1.2. Orthopedic
    • 8.1.3. Surgical Instruments
  • 8.2. Diagnostics
    • 8.2.1. Imaging
    • 8.2.2. Laboratory
    • 8.2.3. Point Of Care
  • 8.3. Feed Supplements
    • 8.3.1. Mineral Supplements
    • 8.3.2. Nutritional Supplements
    • 8.3.3. Vitamin Supplements
  • 8.4. Pharmaceuticals
    • 8.4.1. Anti-Inflammatories
      • 8.4.1.1. Corticosteroids
      • 8.4.1.2. NSAIDs
    • 8.4.2. Anti-Parasitic
      • 8.4.2.1. Ectoparasiticides
      • 8.4.2.2. Endoparasiticides
    • 8.4.3. Antibiotics
      • 8.4.3.1. Beta Lactams
      • 8.4.3.2. Macrolides
      • 8.4.3.3. Tetracyclines
    • 8.4.4. Hormones
      • 8.4.4.1. Growth
      • 8.4.4.2. Reproductive
  • 8.5. Vaccines
    • 8.5.1. Inactivated
    • 8.5.2. Live Attenuated
    • 8.5.3. Recombinant

9. Equine Healthcare Market, by Disease Indication

  • 9.1. Digestive Disorders
    • 9.1.1. Colic
    • 9.1.2. Diarrhea
    • 9.1.3. Ulcers
  • 9.2. Infectious Diseases
    • 9.2.1. Bacterial
    • 9.2.2. Parasitic
    • 9.2.3. Viral
  • 9.3. Musculoskeletal Disorders
    • 9.3.1. Joint Disorders
    • 9.3.2. Orthopedic Injuries
    • 9.3.3. Soft Tissue Injuries
  • 9.4. Reproductive Disorders
    • 9.4.1. Endometritis
    • 9.4.2. Infertility
  • 9.5. Respiratory Disorders
    • 9.5.1. Lower Respiratory
    • 9.5.2. Upper Respiratory

10. Equine Healthcare Market, by Route Of Administration

  • 10.1. Inhalation
    • 10.1.1. Dry Powder
    • 10.1.2. Nebulization
  • 10.2. Injectable
    • 10.2.1. Intramuscular
    • 10.2.2. Intravenous
    • 10.2.3. Subcutaneous
  • 10.3. Oral
    • 10.3.1. Liquids
    • 10.3.2. Powders
    • 10.3.3. Tablets
  • 10.4. Topical
    • 10.4.1. Creams
    • 10.4.2. Gels
    • 10.4.3. Sprays

11. Equine Healthcare Market, by End User

  • 11.1. Equine Owners
    • 11.1.1. Breeding Farms
    • 11.1.2. Individual Owners
  • 11.2. Online Pharmacies
    • 11.2.1. OTC
    • 11.2.2. Prescription
  • 11.3. Research Laboratories
    • 11.3.1. Private
    • 11.3.2. Public
  • 11.4. Veterinary Practices
    • 11.4.1. Large Animal Hospitals
    • 11.4.2. Private Practices

12. Equine Healthcare Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Equine Healthcare Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Equine Healthcare Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Equine Healthcare Market

16. China Equine Healthcare Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Bimeda, Inc.
  • 17.6. Boehringer Ingelheim GmbH
  • 17.7. Ceva Sante Animale S.A.
  • 17.8. Dechra Pharmaceuticals PLC
  • 17.9. Elanco Animal Health Incorporated
  • 17.10. Merck & Co., Inc.
  • 17.11. Norbrook Laboratories Limited
  • 17.12. Vetoquinol S.A.
  • 17.13. Virbac S.A.
  • 17.14. Zoetis Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL EQUINE HEALTHCARE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL EQUINE HEALTHCARE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL EQUINE HEALTHCARE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DISEASE INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES EQUINE HEALTHCARE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA EQUINE HEALTHCARE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL EQUINE HEALTHCARE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ORTHOPEDIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ORTHOPEDIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ORTHOPEDIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY SURGICAL INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY SURGICAL INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY SURGICAL INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY LABORATORY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY LABORATORY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY LABORATORY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY POINT OF CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY POINT OF CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY POINT OF CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY FEED SUPPLEMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY FEED SUPPLEMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY FEED SUPPLEMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY FEED SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY MINERAL SUPPLEMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY MINERAL SUPPLEMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY MINERAL SUPPLEMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY NUTRITIONAL SUPPLEMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY VITAMIN SUPPLEMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY VITAMIN SUPPLEMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY VITAMIN SUPPLEMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PHARMACEUTICALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PHARMACEUTICALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PHARMACEUTICALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ANTI-INFLAMMATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ANTI-INFLAMMATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ANTI-INFLAMMATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY CORTICOSTEROIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY CORTICOSTEROIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY NSAIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY NSAIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY NSAIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ANTI-PARASITIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ANTI-PARASITIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ANTI-PARASITIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ANTI-PARASITIC, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ECTOPARASITICIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ECTOPARASITICIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ECTOPARASITICIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ENDOPARASITICIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ENDOPARASITICIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ENDOPARASITICIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY BETA LACTAMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY BETA LACTAMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY BETA LACTAMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY MACROLIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY MACROLIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY MACROLIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY TETRACYCLINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY TETRACYCLINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY TETRACYCLINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY HORMONES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY HORMONES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY HORMONES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY HORMONES, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY GROWTH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY GROWTH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY GROWTH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY REPRODUCTIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY REPRODUCTIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY REPRODUCTIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY VACCINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY VACCINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY INACTIVATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY INACTIVATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY INACTIVATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY LIVE ATTENUATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY LIVE ATTENUATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY RECOMBINANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY RECOMBINANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY RECOMBINANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DIGESTIVE DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DIGESTIVE DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DIGESTIVE DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DIGESTIVE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY COLIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY COLIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY COLIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DIARRHEA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DIARRHEA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DIARRHEA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ULCERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ULCERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ULCERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY BACTERIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY BACTERIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY BACTERIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PARASITIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PARASITIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PARASITIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY VIRAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY VIRAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY VIRAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY JOINT DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY JOINT DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY JOINT DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ORTHOPEDIC INJURIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ORTHOPEDIC INJURIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ORTHOPEDIC INJURIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY SOFT TISSUE INJURIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY SOFT TISSUE INJURIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY SOFT TISSUE INJURIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY REPRODUCTIVE DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY REPRODUCTIVE DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY REPRODUCTIVE DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY REPRODUCTIVE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ENDOMETRITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ENDOMETRITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ENDOMETRITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY INFERTILITY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY INFERTILITY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY INFERTILITY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY RESPIRATORY DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY RESPIRATORY DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY RESPIRATORY DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY RESPIRATORY DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY LOWER RESPIRATORY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY LOWER RESPIRATORY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY LOWER RESPIRATORY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY UPPER RESPIRATORY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 160. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY UPPER RESPIRATORY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 161. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY UPPER RESPIRATORY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 162. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 163. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY INHALATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 164. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY INHALATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DRY POWDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 168. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DRY POWDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 169. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY DRY POWDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY NEBULIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY NEBULIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 172. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY NEBULIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 174. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 175. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 176. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 177. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 178. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 181. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 184. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 185. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 187. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 189. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 190. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY LIQUIDS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY LIQUIDS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 192. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY LIQUIDS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY POWDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 194. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY POWDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY POWDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 197. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 198. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 200. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 201. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 203. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY CREAMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 204. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY CREAMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 205. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY CREAMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 206. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY GELS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 207. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY GELS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 208. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY GELS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 209. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY SPRAYS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 210. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY SPRAYS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 211. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY SPRAYS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 212. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY EQUINE OWNERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 214. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY EQUINE OWNERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 215. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY EQUINE OWNERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 216. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY EQUINE OWNERS, 2018-2032 (USD MILLION)
  • TABLE 217. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY BREEDING FARMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 218. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY BREEDING FARMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 219. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY BREEDING FARMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 220. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY INDIVIDUAL OWNERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 221. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY INDIVIDUAL OWNERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 222. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY INDIVIDUAL OWNERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 224. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 225. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 226. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 227. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY OTC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 228. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY OTC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 229. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY OTC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 230. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PRESCRIPTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 231. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PRESCRIPTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 232. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PRESCRIPTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 233. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 234. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 235. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 236. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY RESEARCH LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 237. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PRIVATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 238. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PRIVATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 239. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PRIVATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 240. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PUBLIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 241. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PUBLIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 242. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PUBLIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 243. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY VETERINARY PRACTICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 244. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY VETERINARY PRACTICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 245. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY VETERINARY PRACTICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 246. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY VETERINARY PRACTICES, 2018-2032 (USD MILLION)
  • TABLE 247. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY LARGE ANIMAL HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 248. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY LARGE ANIMAL HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 249. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY LARGE ANIMAL HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 250. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PRIVATE PRACTICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 251. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PRIVATE PRACTICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 252. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY PRIVATE PRACTICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 253. GLOBAL EQUINE HEALTHCARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 254. AMERICAS EQUINE HEALTHCARE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 255. AMERICAS EQUINE HEALTHCARE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. AMERICAS EQUINE HEALTHCARE MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 257. AMERICAS EQUINE HEALTHCARE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 258. AMERICAS EQUINE HEALTHCARE MARKET SIZE, BY FEED SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 259. AMERICAS EQUINE HEALTHCARE MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 260. AMERICAS EQUINE HEALTHCARE MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2032 (USD MILLION)
  • TABLE 261. AMERICAS EQUINE HEALTHCARE MARKET SIZE, BY ANTI-PARASITIC, 2018-2032 (USD MILLION)
  • TABLE 262. AMERICAS EQUINE HEALTHCARE MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 263. AMERICAS EQUINE HEALTHCARE MARKET SIZE, BY HORMONES, 2018-2032 (USD MILLION)
  • TABLE 264. AMERICAS EQUINE HEALTHCARE MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 265. AMERICAS EQUINE HEALTHCARE MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 266. AMERICAS EQUINE HEALTHCARE MARKET SIZE, BY DIGESTIVE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 267. AMERICAS EQUINE HEALTHCARE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 268. AMERICAS EQUINE HEALTHCARE MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 269. AMERICAS EQUINE HEALTHCARE MARKET SIZE, BY REPRODUCTIVE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 270. AMERICAS EQUINE HEALTHCARE MARKET SIZE, BY RESPIRATORY DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 271. AMERICAS EQUINE HEALTHCARE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 272. AMERICAS EQUINE HEALTHCARE MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 273. AMERICAS EQUINE HEALTHCARE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 274. AMERICAS EQUINE HEALTHCARE MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 275. AMERICAS EQUINE HEALTHCARE MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 276. AMERICAS EQUINE HEALTHCARE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 277. AMERICAS EQUINE HEALTHCARE MARKET SIZE, BY EQUINE OWNERS, 2018-2032 (USD MILLION)
  • TABLE 278. AMERICAS EQUINE HEALTHCARE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 279. AMERICAS EQUINE HEALTHCARE MARKET SIZE, BY RESEARCH LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 280. AMERICAS EQUINE HEALTHCARE MARKET SIZE, BY VETERINARY PRACTICES, 2018-2032 (USD MILLION)
  • TABLE 281. NORTH AMERICA EQUINE HEALTHCARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 282. NORTH AMERICA EQUINE HEALTHCARE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 283. NORTH AMERICA EQUINE HEALTHCARE MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 284. NORTH AMERICA EQUINE HEALTHCARE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 285. NORTH AMERICA EQUINE HEALTHCARE MARKET SIZE, BY FEED SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 286. NORTH AMERICA EQUINE HEALTHCARE MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 287. NORTH AMERICA EQUINE HEALTHCARE MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2032 (USD MILLION)
  • TABLE 288. NORTH AMERICA EQUINE HEALTHCARE MARKET SIZE, BY ANTI-PARASITIC, 2018-2032 (USD MILLION)
  • TABLE 289. NORTH AMERICA EQUINE HEALTHCARE MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 290. NORTH AMERICA EQUINE HEALTHCARE MARKET SIZE, BY HORMONES, 2018-2032 (USD MILLION)
  • TABLE 291. NORTH AMERICA EQUINE HEALTHCARE MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 292. NORTH AMERICA EQUINE HEALTHCARE MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 293. NORTH AMERICA EQUINE HEALTHCARE MARKET SIZE, BY DIGESTIVE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 294. NORTH AMERICA EQUINE HEALTHCARE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 295. NORTH AMERICA EQUINE HEALTHCARE MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 296. NORTH AMERICA EQUINE HEALTHCARE MARKET SIZE, BY REPRODUCTIVE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 297. NORTH AMERICA EQUINE HEALTHCARE MARKET SIZE, BY RESPIRATORY DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 298. NORTH AMERICA EQUINE HEALTHCARE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 299. NORTH AMERICA EQUINE HEALTHCARE MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 300. NORTH AMERICA EQUINE HEALTHCARE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 301. NORTH AMERICA EQUINE HEALTHCARE MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 302. NORTH AMERICA EQUINE HEALTHCARE MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 303. NORTH AMERICA EQUINE HEALTHCARE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 304. NORTH AMERICA EQUINE HEALTHCARE MARKET SIZE, BY EQUINE OWNERS, 2018-2032 (USD MILLION)
  • TABLE 305. NORTH AMERICA EQUINE HEALTHCARE MARKET SIZE, BY ONLINE PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 306. NORTH AMERICA EQUINE HEALTHCARE MARKET SIZE, BY RESEARCH LABORATORIES, 2018-2032 (USD MILLION)
  • TABLE 307. NORTH AMERICA EQUINE HEALTHCARE MARKET SIZE, BY VETERINARY PRACTICES, 2018-2032 (USD MILLION)
  • TABLE 308. LATIN AMERICA EQUINE HEALTHCARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 309. LATIN AMERICA EQUINE HEALTHCARE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 310. LATIN AMERICA EQUINE HEALTHCARE MARKET SIZE, BY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 311. LATIN AMERICA EQUINE HEALTHCARE MARKET SIZE, BY DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 312. LATIN AMERICA EQUINE HEALTHCARE MARKET SIZE, BY FEED SUPPLEMENTS, 2018-2032 (USD MILLION)
  • TABLE 313. LATIN AMERICA EQUINE HEALTHCARE MARKET SIZE, BY PHARMACEUTICALS, 2018-2032 (USD MILLION)
  • TABLE 314. LATIN AMERICA EQUINE HEALTHCARE MARKET SIZE, BY ANTI-INFLAMMATORIES, 2018-2032 (USD MILLION)
  • TABLE 315. LATIN AMERICA EQUINE HEALTHCARE MARKET SIZE, BY ANTI-PARASITIC, 2018-2032 (USD MILLION)
  • TABLE 316. LATIN AMERICA EQUINE HEALTHCARE MARKET SIZE, BY ANTIBIOTICS, 2018-2032 (USD MILLION)
  • TABLE 317. LATIN AMERICA EQUINE HEALTHCARE MARKET SIZE, BY HORMONES, 2018-2032 (USD MILLION)
  • TABLE 318. LATIN AMERICA EQUINE HEALTHCARE MARKET SIZE, BY VACCINES, 2018-2032 (USD MILLION)
  • TABLE 319. LATIN AMERICA EQUINE HEALTHCARE MARKET SIZE, BY DISEASE INDICATION, 2018-2032 (USD MILLION)
  • TABLE 320. LATIN AMERICA EQUINE HEALTHCARE MARKET SIZE, BY DIGESTIVE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 321. LATIN AMERICA EQUINE HEALTHCARE MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 322. LATIN AMERICA EQUINE HEALTHCARE MARKET SIZE, BY MUSCULOSKELETAL DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 323. LATIN AMERICA EQUINE HEALTHCARE MARKET SIZE, BY REPRODUCTIVE DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 324. LATIN AMERICA EQUINE HEALTHCARE MARKET SIZE, BY RESPIRATORY DISORDERS, 2018-2032 (USD MILLION)
  • TABLE 325. LATIN AMERICA EQUINE HEALTHCARE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 326. LATIN AMERICA EQUINE HEALTHCARE MARKET SIZE, BY INHALATION, 2018-2032 (USD MILLION)
  • TABLE 327. LATIN AMERICA EQUINE HEALTHCARE MARKET SIZE, BY INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 328. LATIN AMERICA EQUINE HEALTHCARE MARKET SIZE, BY ORAL, 2018-2032 (USD MILLION)
  • TABLE 329. LATIN AMERICA EQUINE HEALTHCARE MARKET SIZE, BY TOPICAL, 2018-2032 (USD MILLION)
  • TABLE 330. LATIN AMERICA EQUINE HEALTHCARE MARKET SIZE, BY END US